Sanofi’s (NASDAQ:SNY) growth is propelled by strong demand for its flagship drugs such as Dupixent (for asthma and eczema) ...

With more than 19 million start-ups created over the last three years, Hall said, “American entrepreneurs continue to step ...

SANOFI added a new plant in Singapore to make vaccines and other medicines, as the French pharmaceutical group seeks to ...

Massachusetts Financial Services Co. MA lifted its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 4.8% in the ...

Regeneron Pharmaceuticals Inc. claims that a partner has broken a collaboration deal by refusing to reveal side deals for marketing ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

The FDA has accepted for review the resubmitted sBLA for dupilumab for the treatment of chronic spontaneous urticaria.

Ariel Investments, an investment management company, released its “Ariel Global Fund” third-quarter 2024 investor letter. A ...

Injection Pen Market. The global injection pen market is on track for substantial growth, with a forecasted compound annual ...

This valuation is dirt cheap for a solid biotech company with a robust pipeline. Robust Pipeline To Pump Out Future Growth Regeneron's top blockbuster drug, Dupixent, was recently approved by the FDA ...

Best Genomics Stocks To Buy Right Now. Genomics is the study of genes and how they function. Many rapidly growing companies ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...